Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive ...

Altimmune, Inc. (ALT) on Thursday said that its mid-stage study of Pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) yielded mixed results, sending shares down 57% in morning ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled ...

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) Provided by GlobeNewswire May 19, 2025, 11:30:00 AM ...

After Altimmune (ALT) reported Q3 results and provided an update focused on its lead program pemvidutide, a GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and ...

Altimmune Inc. (NASDAQ:ALT) is poised for a potential breakthrough in the treatment of metabolic-associated steatohepatitis (MASH) and obesity with its lead candidate pemvidutide. With a market ...

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver scarring in patients with fatty liver disease in a mid-stage trial.

Altimmune, Inc. (NASDAQ:ALT), a biotechnology company focused on developing treatments for obesity and liver diseases, has been making waves in the pharmaceutical industry with its lead candidate ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Altimmune (ALT – Research Report) today and set a price target of $12.00. Patrick Trucchio has given his Buy rating due to a ...

Altimmune Inc. (NASDAQ: ALT) is poised for a potential breakthrough in the treatment of metabolic-associated steatohepatitis (MASH) and obesity with its lead candidate pemvidutide.With a market ...

Altimmune Inc. (NASDAQ: ALT) is poised for a potential breakthrough in the treatment of metabolic-associated steatohepatitis (MASH) and obesity with its lead candidate pemvidutide.With a market ...